GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth ...

GenScript is best known for its gene synthesis capabilities, which we estimate is more than half of the life science services and products segment. In 2014, GenScript was the leader in gene synthesis, ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech ...

PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

Building on GenScript's fast and dependable in-vitro transcription mRNA synthesis service, GenScript now offers the most comprehensive range of RNA formats critical, enabling fast delivery of complex ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...

GenScript Biotech provides life science research services and products, and is well known for its gene synthesis capabilities. Its business can roughly be divided into non-cell therapy, or NCT, ...

PISCATAWAY, N.J., July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG ...

Genscript Biotech ( (HK:1548)) just unveiled an update. Genscript Biotech Corporation announced the financial results for the third quarter of 2025 for its associate, Legend Biotech Corporation, which ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...